Skip to content
Biotechnology, Medical Health Aged Care

The Future of Skin Science: InMode and ExoCoBio introduce the most clinically validated exosome technology to New Zealand’s aesthetic market.

InMode Australia 2 mins read

This introduction brings one of the world’s most advanced exosome technologies to New Zealand, with two exclusive events set to take place in:

• Auckland – July 15, 2025 | The Boathouse, Park Hyatt Auckland, from 6:30pm

• Christchurch – July 17, 2025 | Chateau on the Park, DoubleTree by Hilton, from 6:30pm

 

These curated evenings will showcase the powerful synergy between ASCE+ Exosomes and InMode’s Morpheus8 technology, and feature:

• Live treatment demonstrations

• Keynote presentations from leading experts in regenerative science

• Clinical case studies and exclusive launch offers for attending practitioners

 

Key Speakers:

Dr Jean Paul Chung, Aesthetic Physician & Educator (Sydney), will present clinical insights and protocols using ASCE+ in skin rejuvenation.

Mr Byong Seung Cho, CEO & CTO of ExoCoBio, South Korea, will offer a rare insider’s perspective into the research and development behind ASCE+, and its role in reshaping global skin health.

 

Powered by ExoSCRT™, ExoCoBio’s proprietary purification technology, ASCE+ Exosomes are designed to optimise cell-to-cell communication, stimulate repair, and visibly revitalise the skin. Backed by science and trusted globally, ASCE+ is now set to raise the standard for non-invasive skin regeneration in the New Zealand market.

 

Adding to this innovation is the InMode Optimas Max, a powerful multi-platform workstation designed to deliver advanced skin treatments across various modalities -including radiofrequency, IPL, and laser technologies. With applicators such as Morpheus8 Burst, Lumecca Peak, and Forma, Optimas Max offers unparalleled versatility for skin resurfacing, tightening, and pigmentation correction - all in one streamlined device. It enables clinics to offer results-driven treatments with minimal downtime and maximum efficacy.

 

When paired with ASCE+ Exosomes, the Optimas Max system becomes a next-generation aesthetic powerhouse. The synergy between energy-based modalities and regenerative exosome therapy enhances treatment outcomes dramatically - accelerating recovery, improving skin texture, and promoting lasting rejuvenation. This combination delivers a compelling value proposition for clinics and practitioners committed to offering cutting-edge, science-backed solutions for their patients.

 

RSVP – https://event.inmodeau.com/asce_exosomes_nz


About us:

About InMode Australia

InMode is a market leader in energy-based medical technologies, providing cutting-edge, clinically validated solutions across Australia and New Zealand.

 

About ExoCoBio

ExoCoBio is a globally recognised innovator in exosome therapeutics and regenerative aesthetics, dedicated to delivering science-driven skincare solutions through advanced biologics.


Contact details:

Media Contact:
Patricia Amalm
Mobile: 0499 197 069
Email:
[email protected]
Website:
www.inmode.com.au

Follow Us on Instagram

Media

More from this category

  • Medical Health Aged Care
  • 12/11/2025
  • 07:00
RMIT University

Blood test offers hope for more effective ovarian cancer treatment

New clinical research has identified a blood test that can reveal which women are more likely to respond to particular treatment for ovarian cancer,…

  • Contains:
  • Medical Health Aged Care
  • 11/11/2025
  • 16:00
Uniting NSW.ACT

Results of Australia’s first injectable opioid treatment trial announced at 2025 APSAD conference

Media Release 11th November 2025 The results of Australia’s first injectable opioid treatment trial were revealed at the 2025 APSAD (The Australasian Professional Society on Alcohol and other Drugs) conference in Sydney today. Two presentations today outlined the initial findings of the trial – one by Dr Jake Rance, Centre for Social Research in Health at UNSW on ‘The ‘acceptability’ of supervised injectable opioid treatment: Staff and participant reflections from the Australian ‘Feasibility of Injectable Opioid Treatment’ (FOpIT) and the other by Dr Craig Rodgers on the initial outcomes of recruitment, retention and safety. The study is a partnership between…

  • Medical Health Aged Care
  • 11/11/2025
  • 12:26
Samsung Epis Holdings Co., Ltd.

Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms

INCHEON, Korea–BUSINESS WIRE– Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.